PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
The proposed purchase pairs U.S. therapeutic manufacturing capacity with a long-term supply relationship with Lantheus.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PharmaLogic signed a definitive agreement to acquire the contract development and manufacturing business and Springfield, New Jersey facility from Lantheus (LNTH). Financial terms were not disclosed. The acquisition would expand PharmaLogic's U.S. capacity to manufacture radiopharmaceutical therapeutics, drugs that deliver radiation for treatment.
The Springfield facility supports manufacturing, research and clinical development. Its team will join Agilera, PharmaLogic's therapeutic manufacturing franchise, upon completion. The transaction includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus. Closing remains subject to applicable regulatory review and customary closing conditions; the parties will operate independently until closing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Definitive acquisition agreement would add Lantheus' CDMO business and Springfield facility, expanding PharmaLogic's U.S. therapeutic manufacturing capacity.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Long-term supply agreement provides for Agilera to manufacture lutetium Lu 177 dotatate for Lantheus.
Negative
- Minor pointApplicable regulatory review and customary closing conditions remain pending before the acquisition can close.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expands
The
The acquisition expands PharmaLogic's capacity to manufacture radiopharmaceutical therapeutics in the
"This acquisition strengthens Agilera's unique capabilities in radioligand therapies and expands our capacity in the
"We have a long-standing relationship with PharmaLogic, which has been an important manufacturing partner for our PET products," said Mary Anne Heino, Executive Chairperson and Chief Executive Officer of Lantheus. "With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and
The transaction is subject to applicable regulatory review and the satisfaction of other customary closing conditions. The parties will continue to operate independently until the closing.
Advisors
Leerink Partners served as financial advisor to the Company, and Goodwin Procter LLP served as legal advisor.
Solomon Partners Securities LLC served as financial advisor to Lantheus, and Covington & Burling LLP served as legal advisor.
About PharmaLogic Holdings Corp.
PharmaLogic is the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals in
Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and neurology. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries, with a strong track record of inspections by regulators in the
PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit pharmalogicgroup.com and follow us on LinkedIn.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmalogic-to-acquire-lantheus-cdmo-business-and-springfield-new-jersey-manufacturing-facility-302933626.html
SOURCE PharmaLogic Holdings Corp
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is PharmaLogic acquiring from Lantheus?
PharmaLogic agreed to acquire Lantheus' contract development and manufacturing business and its Springfield, New Jersey manufacturing facility. Financial terms were not disclosed. The facility's team will join Agilera upon completion.
What supply agreement accompanies PharmaLogic's acquisition of the Lantheus business?
The transaction includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.